# A regulatory pathway for new radiotherapy techniques modelled on drug development

Source: https://onco.cc/ideas/idea-fund-radiotherapy-innovation-pathway/  
OnCo record `idea-fund-radiotherapy-innovation-pathway` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

New ways of giving radiotherapy are adopted without the staged testing that drugs go through, and are then hard to evaluate. A defined pathway with fee waivers and clear evidence steps would bring rigour without blocking progress.

## Summary

Regulators and professional bodies define a staged pathway for radiotherapy techniques and fractionation innovations (not just machines): technical feasibility and dosimetry standards, early-phase toxicity studies with defined endpoints, randomised or registry-based comparative evaluation, and a clear route to guideline and reimbursement recognition, with regulatory fee waivers and scientific advice for academic sponsors. The machine is regulated as a device but the technique (dose, fractionation, target, adaptation strategy) is what determines outcomes, and it currently has no evidence pathway at all. Radiotherapy groups have called for this for years; making it official aligns academic sponsors, payers and regulators on what evidence is needed.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A defined pathway increases the proportion of new radiotherapy techniques entering clinical use with a prospective comparative study underway from a minority to a majority within four years, and shortens the time from first use to guideline recognition for techniques that prove beneficial.
- Rationale: SBRT and hypofractionation spread for a decade on retrospective data before randomised trials confirmed benefit; FLASH and adaptive radiotherapy are following the same path. Drug development shows staged evidence requirements do not prevent innovation when the pathway is clear and supported.
- Proposed test: Pilot the pathway with three emerging techniques through a regulator-professional body partnership and compare evidence generation and time to recognition with historical techniques.
- Maturity: speculative
- Actor: regulator

## Sources

- ESTRO: https://www.estro.org/

## Connected records

- ideas: [A coordinated FLASH radiotherapy evidence programme with shared dose-rate standards](https://onco.cc/ideas/idea-fund-flash-evidence-programme/), [Core-funded radiotherapy trials infrastructure with central quality assurance](https://onco.cc/ideas/idea-fund-radiotherapy-trials-infrastructure/), [Coverage-with-evidence registries for MR-guided and adaptive radiotherapy](https://onco.cc/ideas/idea-fund-adaptive-radiotherapy-evidence/)
- technologies: [Carbon-ion therapy](https://onco.cc/technologies/carbon-ion/), [FLASH radiotherapy](https://onco.cc/technologies/flash-rt/), [MR-guided adaptive radiotherapy](https://onco.cc/technologies/mr-linac/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- people: [Jürgen Debus](https://onco.cc/people/juergen-debus/), [Michael Baumann](https://onco.cc/people/michael-baumann/)
- bottlenecks: [Regulatory divergence between regions](https://onco.cc/bottlenecks/b-regulatory-fragmentation/), [Surgery and radiotherapy cure most, get least](https://onco.cc/bottlenecks/b-surgery-radiation-innovation/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-radiotherapy-innovation-pathway.json